e-Therapeutics: Discovery Platform Exceeding Expectations; Company Focus Now on Commercialisation

E-Therapeutics plc (AIM:ETX), the drug discovery and development company, today announces its half year results for the six months ended 31 July 2015.

Operational highlights

• ETS2101 – entered phase Ib trials for hepatocellular carcinoma and pancreatic cancer
• ETS6103 - recruited the final patient in H1 in the phase IIb trial for major depressive disorder. Results are expected at the end of FY16
• Discovery platform – fully operational and has generated 10 active discovery projects. Selection of best compounds for formal preclinical development in H1 2016
• Directorate changes – plans to strengthen the Board to reflect new emphasis on commercialisation of assets

Financial highlights

• Cash and liquid resources at £30.2 million (31 January 2015: £33.8 million); operating cash burn in H1 was £5.8m and is expected to increase in H2
• Loss before tax of £5.8 million (H1 2014: loss £5.1 million)
• R&D tax credit of £2.0m received three months earlier than prior year

Professor Malcolm Young, CEO of e-Therapeutics, said:

"The company has made strong progress in all areas during the first six months of the financial year.

"A number of important milestones have been achieved in relation to ETS2101 in cancer and we expect to report the Phase II study results for ETX6103 at the end of the financial year.

"As we stated at the FY results, the discovery platform has exceeded our expectations with respect to productivity and the quality of the candidates being generated. Our primary focus is now on the commercialisation of these opportunities. We are targeting programmes in immuno-oncology and addressing drug resistance in targeted cancer therapies.

"The Company is well positioned for the future, with solid funding, progress in the clinical development programmes as expected and the discovery platform and projects offering exciting prospects for value creation. The second half of the year and 2016 are looking very promising.”

There will be a meeting for analysts at 11.30am today at Instinctif Partners' offices (65 Gresham Street, London EC2V 7NQ). Please contact e-therapeutics@instinctif.com if you wish to attend.

For the full release, please visit the company website at www.etherapeutics.co.uk

About e-Therapeutics plc

e-Therapeutics (AIM: ETX) is a drug discovery and development company with a proprietary discovery platform based on advances in network pharmacology and chemical biology.

The Company is applying its platform to the discovery of new drug candidates. The therapeutic focus of the Company’s discovery activity is in immuno-oncology and addressing drug resistance in targeted cancer therapies. The platform is yielding multiple, highly potent, selective and diverse molecules at much higher yields than is reported for conventional drug discovery.

e-Therapeutics is also advancing its most promising programmes through clinical trials. There is a phase IIb clinical stage drug candidate for major depressive disorder, ETS6103; and a phase Ib clinical stage candidate in hepatocellular and pancreatic cancer, ETS2101. The Company also has a variety of preclinical stage assets, including ETX1153c, a functionally resistance-less antibiotic; ETS2300, telomerase inhibition in anti-cancer; ETS3100, small molecule anti-TNFa; ETS2400 and Hedgehog pathway inhibition.

The Company is fully funded to advance its existing development programmes in cancer and depression and a further programme from its discovery platform. It is based at sites in Oxford and Newcastle, UK. For more information about the Company, please visit www.etherapeutics.co.uk.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150928006768/en/